NeuroSense Announces First Quarter 2024 Business Update
NeuroSense Therapeutics Ltd. (Nasdaq: NRSN) ("NeuroSense"), a company developing novel treatments for severe neurodegenerative diseases, today...
NeuroSense Shares Are Trading Higher After the Company Announced an Alzheimer's Drug Development Collaboration With Genetika+.
NeuroSense Shares Are Trading Higher After the Company Announced an Alzheimer's Drug Development Collaboration With Genetika+.
NeuroSense and Genetika+ Initiate Precision Medicine Collaboration Beginning With Ongoing Phase 2 Clinical Trial in Alzheimer's Disease
NeuroSense Therapeutics Ltd. (NASDAQ: NRSN) ("NeuroSense"), a company developing novel treatments for severe neurodegenerative diseases announced...
NeuroSense Presents Positive Data Validating Phase 2b Topline Readout During Emerging Science Presentation at the American Academy of Neurology Annual Meeting
NeuroSense Therapeutics Ltd. (NASDAQ: NRSN) ("NeuroSense"), a company developing novel treatments for severe neurodegenerative diseases, announces...
NeuroSense to Present PARADIGM Data at the American Academy of Neurology Annual Meeting April 16, 2024
NeuroSense Therapeutics Ltd. (Nasdaq: NRSN) ("NeuroSense"), a company developing novel treatments for severe neurodegenerative diseases, announces...
Reported Earlier, NeuroSense Therapeutics Prices $4.5M Registered Direct Offering Of 2.98M Shares And Concurrent Private Placement
NeuroSense Therapeutics Ltd, a company developing novel treatments for severe neurodegenerative diseases, today announced it has entered into a securities purchase agreement with a single health-care
NeuroSense Announces Pricing of $4.5 Million Registered Direct Offering and Concurrent Private Placement
CAMBRIDGE, Mass., April 10, 2024 /PRNewswire/ -- NeuroSense Therapeutics Ltd. (Nasdaq: NRSN) ("NeuroSense" or the "Company"), a company developing novel treatments for severe neurodegenerative diseas
NeuroSense Therapeutics GAAP EPS of -$0.83 Misses by $0.01
NeuroSense Therapeutics Q4 EPS $(0.16) Beats $(0.23) Estimate
NeuroSense Therapeutics (NASDAQ:NRSN) reported quarterly losses of $(0.16) per share which beat the analyst consensus estimate of $(0.23) by 30.43 percent. This is a 40.74 percent increase over losses
XXII, GRIN and XTIA Are Among Mid-day Movers
NeuroSense Therapeutics Had Cash of $2.6M at Dec 31 >NRSN
NeuroSense Therapeutics Had Cash of $2.6M at Dec 31 >NRSN
NeuroSense FY23 EPS $(0.83) Beats $(0.85) Estimate
NeuroSense FY23 EPS $(0.83) Beats $(0.85) Estimate
Press Release: NeuroSense Announces Year End 2023 Financial Results and Provides Business Update
CAMBRIDGE, Mass., April 5, 2024 /PRNewswire/ -- NeuroSense Therapeutics Ltd. (NASDAQ: NRSN) ("NeuroSense"), a company developing novel treatments for severe neurodegenerative diseases, today reported its financial results for the year ended December 31, 2023 and provides a business update.
NeuroSense Reports Additional Positive Results From Its ALS Phase 2b PARADIGM Trial
NeuroSense Therapeutics Ltd. (Nasdaq: NRSN) ("NeuroSense"), a company developing treatments for severe neurodegenerative diseases, today reports...
NeuroSense Regains Compliance With NASDAQ Minimum Bid Price Rule
NeuroSense Therapeutics Ltd. (Nasdaq: NRSN) ("NeuroSense"), a company developing treatments for severe neurodegenerative diseases, today announced...
NeuroSense's (NASDAQ:NRSN) ALS Drug Candidate Shows Promise In Recent Phase 2b Trial; More Milestones To Come In 2024
NeuroSense Reviews 2023 Achievements; Provides Road Map For 2024
End of Phase 2 meeting with the FDA and EMA expected in Q2 2024 and several biomarker study results anticipated as early as Q1 2024, as the Company advances partnership discussionsStatistically Signif
NeuroSense Recaps Positive 2023 Achievements Including Statistically Significant Slowing of Disease Progression in Phase 2b ALS Trial of PrimeC and Highlights Anticipated 2024 Catalysts
NeuroSense Therapeutics Ltd. (NASDAQ: NRSN) ("NeuroSense"), a company developing treatments for severe neurodegenerative diseases, shares a review of ...
NeuroSense Gets Non-Compliance Notice From Nasdaq
NeuroSense Therapeutics (NRSN) said late Wednesday it has received a notice from the Nasdaq Stock Market that it is not compliant with the minimum stockholders' equity requirement for continued listin
NeuroSense Therapeutics Gets Notice From Nasdaq
No Data